Physician
Lawrence and Memorial Hospital, INC.
Lawrence and Memorial Hospital, INC. was paid $136.19M by Medicaid between Jan 2018 and Dec 2024, across 551 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider infoLAWRENCE AND MEMORIAL HOSPITAL, INC.
NEW LONDON, CT 06320
NEW LONDON, CT 06320
33aNPI1700092459assigned 05/16/2007
33bProvider typeInternal Medicine Physician
28Total paid$136.19M
24GClaims4,077,349
24DCodes billed551
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Connecticut
Rank by total paid#2 of 295
Median peer was paid$35K
This provider vs. median3,872×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WRINN, JACQUELINE controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 487,317 | $16.42M | |
| 2019 | 515,982 | $17.53M | |
| 2020 | 490,496 | $14.60M | |
| 2021 | 637,474 | $20.71M | |
| 2022 | 679,012 | $24.10M | |
| 2023 | 686,604 | $23.08M | |
| 2024incomplete | 580,464 | $19.75M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 104,180 | 93,085 | $24.10M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 41,416 | 36,244 | $22.83M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 125,593 | 114,532 | $17.14M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.5% | 85,275 | 26,030 | $4.82M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 31,128 | 25,008 | $4.35M |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 2.9% | 26,932 | 23,935 | $3.99M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.9% | 37,743 | 28,016 | $2.52M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 25,389 | 8,537 | $2.41M |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.7% | 12,589 | 11,181 | $2.35M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 11,814 | 10,712 | $2.19M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 17,171 | 15,528 | $2.17M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 34,609 | 29,199 | $2.14M |
539 more codes
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 33,016 | $1.89M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 1.3% | 1,991 | $1.74M |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 30,970 | $1.72M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 6,942 | $1.64M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 25,726 | $1.29M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 1,608 | $1.28M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,994 | $1.21M |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,363 | $1.19M |
| G0384 | Level 5 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 3,744 | $1.17M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 10,263 | $1.13M |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 20,270 | $879K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 6,730 | $869K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,954 | $848K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,259 | $644K |
| 62323 | <1% | 1,341 | $640K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,529 | $637K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 44,798 | $622K |
| 97162 | <1% | 11,906 | $611K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,878 | $610K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 12,434 | $610K |
| 92587 | <1% | 2,577 | $589K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 5,273 | $566K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 28,281 | $549K |
| 59025 | Fetal non-stress test | <1% | 3,458 | $539K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,187 | $523K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 847 | $510K |
| 95911 | <1% | 1,289 | $502K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 4,873 | $469K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 3,240 | $468K |
| 76830 | Ultrasound, transvaginal | <1% | 4,713 | $458K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,769 | $420K |
| 71045 | Radiologic examination, chest; single view | <1% | 8,901 | $416K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 62 | $402K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,139 | $374K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 4,061 | $350K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 4,449 | $348K |
| 72141 | <1% | 1,689 | $348K | |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 3,759 | $346K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 2,804 | $339K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,033 | $339K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 841 | $324K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 34,185 | $310K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 16,004 | $304K |
| 93976 | <1% | 3,245 | $300K | |
| 94060 | <1% | 1,593 | $291K | |
| 70498 | <1% | 1,589 | $288K | |
| 76770 | <1% | 3,394 | $279K | |
| 64493 | <1% | 339 | $278K | |
| 97014 | <1% | 3,689 | $254K | |
| 76801 | <1% | 2,533 | $253K | |
| 97166 | <1% | 4,551 | $250K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 1,227 | $249K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 147,745 | $248K |
| 93798 | <1% | 3,706 | $244K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 2,870 | $238K |
| 86900 | <1% | 7,651 | $237K | |
| 82947 | <1% | 106,586 | $230K | |
| 76536 | <1% | 3,067 | $225K | |
| 93971 | <1% | 3,179 | $218K | |
| 10060 | <1% | 1,374 | $213K | |
| 72100 | <1% | 5,863 | $209K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 10,216 | $207K |
| 97035 | <1% | 3,150 | $201K | |
| 92523 | <1% | 815 | $195K | |
| 97161 | <1% | 3,073 | $195K | |
| 76642 | <1% | 3,018 | $194K | |
| 95811 | <1% | 269 | $194K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,548 | $168K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 8,601 | $167K |
| 97116 | <1% | 5,394 | $157K | |
| 71250 | <1% | 2,788 | $156K | |
| 81513 | <1% | 2,362 | $153K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 10,253 | $151K |
| 77065 | Tomosynthesis, mammo | <1% | 1,354 | $149K |
| 74183 | <1% | 859 | $149K | |
| 93017 | <1% | 3,212 | $148K | |
| 93970 | <1% | 1,176 | $146K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,170 | $146K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 595 | $139K |
| 83718 | <1% | 19,408 | $139K | |
| 86003 | <1% | 1,525 | $138K | |
| 73221 | <1% | 876 | $135K | |
| 82247 | <1% | 72,042 | $134K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 165,638 | $133K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,599 | $128K |
| 72197 | <1% | 555 | $125K | |
| 82040 | <1% | 73,167 | $116K | |
| 73564 | <1% | 4,641 | $110K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 19,621 | $104K |
| 76641 | <1% | 1,171 | $104K | |
| 92579 | <1% | 1,391 | $104K | |
| 97012 | <1% | 1,495 | $98K | |
| 52000 | <1% | 324 | $94K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 792 | $92K |
| 96415 | <1% | 1,494 | $89K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,281 | $89K |
| 70491 | <1% | 571 | $88K | |
| 71271 | <1% | 947 | $87K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 8,095 | $85K |
| 87481 | <1% | 2,364 | $85K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,947 | $79K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,074 | $79K |
| 77080 | <1% | 773 | $77K | |
| 82310 | <1% | 105,992 | $77K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 37,753 | $77K |
| 82728 | <1% | 11,679 | $76K | |
| 76882 | <1% | 1,120 | $75K | |
| 93880 | <1% | 1,016 | $74K | |
| 36430 | <1% | 484 | $72K | |
| 82607 | <1% | 8,787 | $71K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 31,474 | $70K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,975 | $70K |
| 92557 | <1% | 2,041 | $68K | |
| 73030 | <1% | 4,822 | $65K | |
| 87506 | <1% | 713 | $62K | |
| 70486 | <1% | 1,483 | $61K | |
| 84439 | <1% | 10,964 | $61K | |
| 72158 | <1% | 315 | $60K | |
| 87536 | <1% | 951 | $59K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,725 | $59K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 25 | $58K |
| 83970 | <1% | 2,739 | $57K | |
| 83550 | <1% | 12,398 | $53K | |
| 72040 | <1% | 2,178 | $51K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 222 | $51K |
| 86780 | <1% | 4,699 | $51K | |
| 86803 | <1% | 6,215 | $50K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 101 | $49K |
| 74018 | <1% | 1,434 | $47K | |
| 72070 | <1% | 1,349 | $47K | |
| 73630 | <1% | 5,030 | $45K | |
| 29581 | <1% | 602 | $45K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 25,781 | $45K |
| 93225 | <1% | 754 | $44K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,442 | $43K |
| 73502 | <1% | 2,920 | $41K | |
| 96417 | <1% | 1,030 | $40K | |
| 83540 | <1% | 12,473 | $40K | |
| 95910 | <1% | 208 | $40K | |
| 72131 | <1% | 760 | $39K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 70 | $39K |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 157 | $38K |
| 86480 | <1% | 944 | $38K | |
| 97597 | <1% | 471 | $37K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16,330 | $37K |
| 73610 | <1% | 4,942 | $34K | |
| 82746 | <1% | 4,012 | $33K | |
| 84403 | <1% | 1,980 | $33K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 274 | $31K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 46 | $31K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 2,320 | $31K |
| 83880 | <1% | 4,613 | $30K | |
| 73130 | <1% | 3,491 | $30K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 285 | $30K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,997 | $29K |
| 86618 | <1% | 5,126 | $29K | |
| 82374 | <1% | 105,819 | $29K | |
| 73560 | <1% | 2,620 | $28K | |
| 97163 | <1% | 593 | $27K | |
| 77336 | <1% | 490 | $26K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 601 | $23K |
| 86360 | <1% | 677 | $23K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 192 | $23K |
| 73110 | <1% | 2,740 | $22K | |
| 87480 | <1% | 1,833 | $22K | |
| 87660 | <1% | 1,832 | $22K | |
| 87510 | <1% | 1,832 | $22K | |
| 87150 | <1% | 1,194 | $21K | |
| 84702 | <1% | 5,862 | $21K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 240 | $21K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,812 | $21K |
| 84153 | <1% | 2,507 | $20K | |
| 86038 | <1% | 2,802 | $20K | |
| 85027 | <1% | 12,167 | $20K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 278 | $19K |
| 82570 | <1% | 7,152 | $19K | |
| 81001 | <1% | 43,044 | $19K | |
| 62322 | <1% | 41 | $19K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,156 | $19K |
| 29580 | <1% | 322 | $18K | |
| 86140 | <1% | 9,476 | $18K | |
| 82784 | <1% | 2,854 | $17K | |
| 85610 | <1% | 13,611 | $17K | |
| 87186 | <1% | 8,451 | $17K | |
| 96411 | <1% | 279 | $17K | |
| 87340 | <1% | 4,224 | $16K | |
| 83735 | <1% | 17,799 | $16K | |
| 97165 | <1% | 304 | $16K | |
| 87077 | <1% | 8,105 | $16K | |
| 70496 | <1% | 1,618 | $15K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | <1% | 125 | $15K |
| 84480 | <1% | 1,437 | $15K | |
| 73140 | <1% | 2,365 | $15K | |
| 97167 | <1% | 216 | $15K | |
| 84146 | <1% | 1,146 | $15K | |
| 82042 | <1% | 5,126 | $14K | |
| 80061 | Lipid panel | <1% | 6,850 | $14K |
| 70544 | <1% | 55 | $14K | |
| 52310 | <1% | 12 | $14K | |
| 85055 | <1% | 2,689 | $13K | |
| 82785 | <1% | 1,082 | $13K | |
| 74178 | <1% | 70 | $13K | |
| 77062 | <1% | 939 | $13K | |
| 83001 | <1% | 985 | $13K | |
| 86617 | <1% | 951 | $12K | |
| 83516 | <1% | 864 | $12K | |
| V5264 | Ear mold/insert, not disposable, any type | <1% | 310 | $12K |
| 94010 | <1% | 102 | $12K | |
| 87070 | <1% | 5,930 | $11K | |
| 93923 | <1% | 148 | $11K | |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 312 | $10K |
| 92526 | <1% | 173 | $10K | |
| 82465 | <1% | 19,511 | $10K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 3,019 | $10K |
| 71101 | <1% | 1,256 | $9K | |
| V5266 | Battery for use in hearing device | <1% | 656 | $9K |
| 62321 | <1% | 18 | $9K | |
| 85652 | <1% | 6,609 | $9K | |
| 86850 | <1% | 7,004 | $9K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,479 | $9K |
| 73590 | <1% | 1,164 | $8K | |
| 96367 | <1% | 269 | $8K | |
| 74174 | <1% | 63 | $8K | |
| 85007 | <1% | 9,429 | $8K | |
| 80053 | Comprehensive metabolic panel | <1% | 29,574 | $8K |
| 84270 | <1% | 505 | $8K | |
| 77334 | <1% | 59 | $8K | |
| 73080 | <1% | 1,555 | $8K | |
| 72110 | <1% | 135 | $7K | |
| 95909 | <1% | 39 | $7K | |
| 86359 | <1% | 676 | $7K | |
| 80164 | <1% | 1,552 | $7K | |
| 73522 | <1% | 201 | $7K | |
| 83002 | <1% | 512 | $7K | |
| 86706 | <1% | 1,144 | $7K | |
| 77061 | <1% | 521 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 17 | $6K |
| 84425 | <1% | 440 | $6K | |
| G0378 | Hospital observation service, per hour | <1% | 26,127 | $6K |
| 77300 | <1% | 46 | $6K | |
| 82140 | <1% | 1,427 | $6K | |
| 86709 | <1% | 877 | $6K | |
| 86705 | <1% | 859 | $6K | |
| 86364 | <1% | 742 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 195 | $6K |
| 74019 | <1% | 1,776 | $6K | |
| 84478 | <1% | 19,908 | $6K | |
| 83690 | <1% | 20,720 | $6K | |
| 82950 | <1% | 1,349 | $5K | |
| 87640 | <1% | 264 | $5K | |
| 29515 | <1% | 43 | $5K | |
| 83655 | <1% | 502 | $5K | |
| 86431 | <1% | 1,552 | $5K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 1,472 | $5K |
| 82105 | <1% | 635 | $5K | |
| V5160 | Dispensing fee, binaural | <1% | 12 | $5K |
| 86762 | <1% | 1,812 | $5K | |
| 85730 | <1% | 2,883 | $4K | |
| 87653 | <1% | 194 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 524 | $4K |
| 96402 | <1% | 708 | $4K | |
| 73562 | <1% | 108 | $4K | |
| 84156 | <1% | 2,834 | $4K | |
| 86800 | <1% | 405 | $4K | |
| 51798 | <1% | 2,418 | $4K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 152 | $4K |
| 95819 | <1% | 31 | $4K | |
| 0240U | <1% | 38 | $4K | |
| 83721 | <1% | 933 | $4K | |
| 82670 | <1% | 198 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 289 | $4K |
| 84165 | <1% | 1,221 | $3K | |
| 86787 | <1% | 1,189 | $3K | |
| 87484 | <1% | 388 | $3K | |
| 87468 | <1% | 384 | $3K | |
| 92567 | <1% | 4,122 | $3K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 241 | $3K |
| 84703 | <1% | 25,685 | $3K | |
| 86334 | <1% | 498 | $3K | |
| 86376 | <1% | 350 | $3K | |
| 87493 | <1% | 201 | $3K | |
| 82565 | <1% | 110,284 | $3K | |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 40 | $3K |
| 87205 | <1% | 3,563 | $3K | |
| 87631 | <1% | 1,323 | $3K | |
| 88142 | <1% | 219 | $3K | |
| 73660 | <1% | 376 | $3K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 34 | $3K |
| 92611 | <1% | 27 | $3K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 11,102 | $3K |
| 95812 | <1% | 13 | $3K | |
| 81003 | <1% | 10,361 | $3K | |
| 73090 | <1% | 582 | $3K | |
| 73700 | <1% | 43 | $3K | |
| 82248 | <1% | 8,992 | $3K | |
| 86258 | <1% | 181 | $2K | |
| 76857 | <1% | 42 | $2K | |
| 72050 | <1% | 25 | $2K | |
| 85379 | <1% | 5,520 | $2K | |
| 86665 | <1% | 132 | $2K | |
| 74230 | <1% | 27 | $2K | |
| 83013 | <1% | 37 | $2K | |
| 93308 | <1% | 13 | $2K | |
| 72081 | <1% | 28 | $2K | |
| 87075 | <1% | 1,846 | $2K | |
| 82533 | <1% | 176 | $2K | |
| 86235 | <1% | 61 | $2K | |
| 87040 | <1% | 6,800 | $2K | |
| 83525 | <1% | 212 | $2K | |
| 93271 | <1% | 24 | $2K | |
| 83521 | <1% | 483 | $2K | |
| 84145 | <1% | 994 | $2K | |
| 85046 | <1% | 1,520 | $2K | |
| 87207 | <1% | 1,059 | $1K | |
| 76978 | <1% | 13 | $1K | |
| 86696 | <1% | 125 | $1K | |
| 72170 | <1% | 241 | $1K | |
| 86200 | <1% | 146 | $1K | |
| 76775 | <1% | 57 | $1K | |
| 84550 | <1% | 3,327 | $1K | |
| 84132 | <1% | 106,552 | $1K | |
| 84402 | <1% | 54 | $1K | |
| 86308 | <1% | 1,124 | $1K | |
| 85014 | <1% | 1,939 | $1K | |
| 51702 | <1% | 44 | $1K | |
| 86695 | <1% | 125 | $982.80 | |
| 82550 | <1% | 8,044 | $951.94 | |
| 86664 | <1% | 129 | $949.65 | |
| 92582 | <1% | 28 | $949.12 | |
| 84450 | <1% | 73,418 | $903.59 | |
| 73552 | <1% | 108 | $891.95 | |
| 12002 | <1% | 437 | $880.33 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,065 | $857.04 |
| 82951 | <1% | 78 | $848.01 | |
| 86039 | <1% | 132 | $836.91 | |
| 83883 | <1% | 179 | $780.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 836 | $709.65 |
| 84436 | <1% | 155 | $692.69 | |
| 12011 | <1% | 1,080 | $673.20 | |
| 86160 | <1% | 64 | $653.79 | |
| 92555 | <1% | 1,943 | $632.19 | |
| 84484 | <1% | 28,879 | $629.64 | |
| 84520 | <1% | 107,067 | $622.65 | |
| 82435 | <1% | 105,795 | $594.94 | |
| 82378 | <1% | 394 | $587.45 | |
| 85018 | <1% | 541 | $565.45 | |
| 84410 | <1% | 14 | $507.90 | |
| 12001 | <1% | 2,033 | $493.84 | |
| 83615 | <1% | 2,077 | $486.20 | |
| 84460 | <1% | 71,767 | $481.92 | |
| 0031A | <1% | 16 | $480.00 | |
| 83520 | <1% | 63 | $469.68 | |
| 86769 | <1% | 13 | $463.43 | |
| 94618 | <1% | 38 | $453.19 | |
| 94664 | <1% | 1,782 | $415.79 | |
| 87632 | <1% | 102 | $407.66 | |
| 82962 | <1% | 29,650 | $381.36 | |
| 90686 | <1% | 77 | $380.60 | |
| 86225 | <1% | 52 | $380.48 | |
| 86255 | <1% | 27 | $379.83 | |
| 83021 | <1% | 49 | $379.28 | |
| 82150 | <1% | 133 | $370.16 | |
| 86704 | <1% | 78 | $368.32 | |
| 84630 | <1% | 42 | $347.84 | |
| 81025 | <1% | 3,100 | $338.24 | |
| 88342 | <1% | 443 | $335.92 | |
| 87081 | <1% | 75 | $329.68 | |
| 86920 | <1% | 82 | $315.68 | |
| 76870 | <1% | 1,031 | $294.25 | |
| 83605 | <1% | 5,313 | $277.43 | |
| 29125 | <1% | 686 | $249.79 | |
| 83014 | <1% | 37 | $240.32 | |
| 82627 | <1% | 13 | $233.53 | |
| 88304 | <1% | 1,106 | $229.39 | |
| 87252 | <1% | 13 | $224.01 | |
| 87209 | <1% | 27 | $223.25 | |
| 84295 | <1% | 106,064 | $222.06 | |
| 87449 | <1% | 94 | $196.52 | |
| 86923 | <1% | 49 | $174.30 | |
| 83921 | <1% | 26 | $172.92 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,206 | $172.56 |
| 80178 | <1% | 62 | $170.37 | |
| 84075 | <1% | 71,040 | $165.22 | |
| 84100 | <1% | 3,629 | $163.79 | |
| 87177 | <1% | 26 | $161.50 | |
| 82803 | <1% | 1,606 | $149.28 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,404 | $144.48 |
| 87324 | <1% | 65 | $139.27 | |
| 36591 | <1% | 38 | $137.02 | |
| 73060 | <1% | 102 | $130.19 | |
| J3490 | Unclassified drugs | <1% | 204,315 | $119.40 |
| 90715 | <1% | 2,946 | $102.14 | |
| 82977 | <1% | 333 | $97.47 | |
| 87807 | <1% | 378 | $91.60 | |
| 84155 | <1% | 70,870 | $72.86 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 28,705 | $58.79 |
| 88112 | <1% | 28 | $57.27 | |
| 87430 | <1% | 1,416 | $57.25 | |
| 88312 | <1% | 575 | $55.57 | |
| 81002 | <1% | 222 | $53.68 | |
| 80177 | <1% | 22 | $50.64 | |
| G0659 | Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes | <1% | 1,049 | $43.60 |
| 81000 | <1% | 81 | $43.52 | |
| 94726 | <1% | 41 | $42.50 | |
| 86300 | <1% | 192 | $39.74 | |
| 95012 | <1% | 191 | $36.77 | |
| 83010 | <1% | 27 | $36.03 | |
| 82952 | <1% | 12 | $33.66 | |
| 87184 | <1% | 41 | $32.95 | |
| 80050 | General health panel | <1% | 25 | $30.96 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 13,250 | $20.14 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 135 | $20.00 |
| 86304 | <1% | 19 | $19.87 | |
| 96376 | <1% | 5,591 | $18.59 | |
| 80051 | <1% | 100 | $16.02 | |
| 80076 | <1% | 31 | $15.60 | |
| 97164 | <1% | 13 | $15.17 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 1,364 | $14.93 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 169 | $13.23 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,686 | $12.09 |
| J3535 | Drug administered through a metered dose inhaler | <1% | 722 | $11.22 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 2,502 | $10.02 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,264 | $7.60 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,654 | $7.22 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 30,327 | $4.96 |
| 87210 | <1% | 726 | $4.07 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,299 | $3.22 |
| 86901 | <1% | 7,643 | $2.64 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 361 | $2.62 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 2,257 | $2.27 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 314 | $2.25 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,575 | $1.96 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,020 | $1.47 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,933 | $1.27 |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 464 | $1.20 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 7,736 | $1.09 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 10,873 | $0.97 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,485 | $0.54 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,778 | $0.47 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 6,594 | $0.28 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 18 | $0.06 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 18 | $0.06 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 7,531 | $0.02 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 818 | $0.00 |
| 99152 | 0% | 5,160 | $0.00 | |
| 80143 | 0% | 251 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,614 | $0.00 |
| Q9954 | Oral magnetic resonance contrast agent, per 100 ml | 0% | 1,403 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 170 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 4,423 | $0.00 |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | 0% | 53 | $0.00 |
| 94729 | 0% | 1,418 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 299 | $0.00 |
| 93325 | 0% | 893 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 483 | $0.00 |
| 93226 | 0% | 738 | $0.00 | |
| 76376 | 0% | 751 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 6,715 | $0.00 |
| 94727 | 0% | 857 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 2,951 | $0.00 |
| 76937 | 0% | 719 | $0.00 | |
| 93321 | 0% | 29 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 2,254 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 295 | $0.00 |
| 77012 | 0% | 27 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 217 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 101 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 238 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 1,449 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 297 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 87 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 70 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 109 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 48 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 59 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 47 | $0.00 |
| 77002 | 0% | 12 | $0.00 | |
| 93356 | 0% | 85 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 58 | $0.00 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 53 | $0.00 |
| 97602 | 0% | 25 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 69 | $0.00 |
| C1729 | Catheter, drainage | 0% | 20 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 13 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 54 | $0.00 |
| 64495 | 0% | 107 | $0.00 | |
| C1758 | Catheter, ureteral | 0% | 13 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 21 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 12 | $0.00 |
| 36592 | 0% | 12 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 17 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 12,103 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 1,105 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 346 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 6,457 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 12,275 | $0.00 |
| 95886 | 0% | 1,422 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 1,752 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,036 | $0.00 |
| V2632 | Posterior chamber intraocular lens | 0% | 76 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 2,002 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 2,580 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 11,058 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 101 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 2,915 | $0.00 |
| 95885 | 0% | 657 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 560 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 233 | $0.00 |
| 88341 | 0% | 162 | $0.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 3,905 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 4,335 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 1,569 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 575 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 13 | $0.00 |
| 88307 | 0% | 84 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 2,511 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 150 | $0.00 |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | 0% | 100 | $0.00 |
| 87808 | 0% | 581 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 411 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 224 | $0.00 |
| 93320 | 0% | 195 | $0.00 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | 0% | 2,519 | $0.00 |
| 64494 | 0% | 288 | $0.00 | |
| C1769 | Guide wire | 0% | 518 | $0.00 |
| 91303 | 0% | 14 | $0.00 | |
| 80069 | 0% | 20 | $0.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 24 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 32 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 36 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 377 | $0.00 |
| 96368 | 0% | 19 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 15 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 29 | $0.00 |
| 87015 | 0% | 22 | $0.00 | |
| 88108 | 0% | 13 | $0.00 | |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 31 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 64 | $0.00 |
| 77001 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWRINN, JACQUELINE (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| Yale New Haven Hospital | New Haven, CT | $1.08B |
| Bridgeport Hospital | Bridgeport, CT | $287.34M |
| Greenwich Hospital | Greenwich, CT | $46.42M |
| Bridgeport Hospital | Milford, CT | $15.60M |
| LMW Healthcare INC. | Westerly, RI | $13.10M |
| Lawrence and Memorial Hospital, INC. | New London, CT | $1.55M |
| Yale New Haven Hospital | New Haven, CT | $629K |
| LMW Healthcare INC. | Westerly, RI | $492K |
| Bridgeport Hospital | Bridgeport, CT | $398K |
| Lawrence and Memorial Hospital, INC. | New London, CT | $365K |
| Shoreline Endoscopy Center, LLC | Guilford, CT | $19K |
| Yale New Haven Hospital | New Haven, CT | $860.83 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.